{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:13:47Z","timestamp":1794366827600,"version":"4.9.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-025-01432-6","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T05:03:16Z","timestamp":1750914196000},"page":"178-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8888-7096","authenticated-orcid":false,"given":"Tony","family":"Georgiev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Migliorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7841-1964","authenticated-orcid":false,"given":"Andrea","family":"Ciamarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7277-1246","authenticated-orcid":false,"given":"Marco","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8567-9013","authenticated-orcid":false,"given":"Ilaria","family":"Biancofiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinuccia","family":"Faviana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2702-3259","authenticated-orcid":false,"given":"Francesco","family":"Bartoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Seo","family":"Park Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Principi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2010-2667","authenticated-orcid":false,"given":"Ettore","family":"Gilardoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6538-7379","authenticated-orcid":false,"given":"Nicholas","family":"Favalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Puca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2013-7381","authenticated-orcid":false,"given":"Sebastian","family":"Oehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0510-5664","authenticated-orcid":false,"given":"Samuele","family":"Cazzamalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"1432_CR1","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1007\/s00259-010-1489-y","volume":"37","author":"AAM Van Der Veldt","year":"2010","unstructured":"Van Der Veldt, A. A. M. et al. Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients. Eur. J. Nucl. Med. Mol. Imaging 37, 1950\u20131958 (2010).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1432_CR2","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1158\/1078-0432.CCR-12-3779","volume":"19","author":"AAM Van Der Veldt","year":"2013","unstructured":"Van Der Veldt, A. A. M. et al. Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [11C]docetaxel and positron emission tomography. Clin. Cancer Res. 19, 4163\u20134173 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1432_CR3","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem, E. et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V25 study group. J. Clin. Oncol. 24, 4991\u20134997 (2006).","journal-title":"J. Clin. Oncol."},{"key":"1432_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/abt\/tbac021","volume":"5","author":"X Lyu","year":"2022","unstructured":"Lyu, X. et al. The global landscape of approved antibody therapies. Antibody Ther. 5, 233\u2013257 (2022).","journal-title":"Antibody Ther."},{"key":"1432_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1158\/0008-5472.CAN-06-2531","volume":"67","author":"MS Dennis","year":"2007","unstructured":"Dennis, M. S. et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res. 67, 254\u2013261 (2007).","journal-title":"Cancer Res."},{"key":"1432_CR6","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1021\/jacs.7b13361","volume":"140","author":"S Cazzamalli","year":"2018","unstructured":"Cazzamalli, S., Dal Corso, A., Widmayer, F. & Neri, D. Chemically defined antibody- and small molecule-drug conjugates for in vivo tumor targeting applications: a comparative analysis. J. Am. Chem. Soc. 140, 1617\u20131621 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"1432_CR7","doi-asserted-by":"crossref","unstructured":"Lu, G. et al. Co-administered antibody improves penetration of antibody\u2013dye conjugate into human cancers with implications for antibody\u2013drug conjugates. Nat. Commun. 11, 5667 (2020).","DOI":"10.1038\/s41467-020-19498-y"},{"key":"1432_CR8","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber, G. M., Schmidt, M. M. & Wittrup, K. D. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 60, 1421\u20131434 (2008).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1432_CR9","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1208\/s12248-016-9940-z","volume":"18","author":"C Cilliers","year":"2016","unstructured":"Cilliers, C., Guo, H., Liao, J., Christodolu, N. & Thurber, G. M. Multiscale modeling of antibody\u2013drug conjugates: connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy. AAPS J. 18, 1117\u20131130 (2016).","journal-title":"AAPS J."},{"key":"1432_CR10","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1021\/acs.bioconjchem.3c00244","volume":"34","author":"A Zana","year":"2023","unstructured":"Zana, A. et al. A comparative analysis of fibroblast activation protein-targeted small molecule\u2013drug, antibody\u2013drug, and peptide\u2013drug conjugates. Bioconjugate Chem. 34, 1205\u20131211 (2023).","journal-title":"Bioconjugate Chem."},{"key":"1432_CR11","first-page":"3752","volume":"55","author":"F Yuan","year":"1995","unstructured":"Yuan, F. et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752\u20133756 (1995).","journal-title":"Cancer Res."},{"key":"1432_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg, J. et al. Phase 3 trial of 177 Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125\u2013135 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1432_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor, O. et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091\u20131103 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1432_CR14","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","volume":"162","author":"JP Hughes","year":"2011","unstructured":"Hughes, J. P., Rees, S. S., Kalindjian, S. B. & Philpott, K. L. Principles of early drug discovery. Br. J. Pharmacol. 162, 1239\u20131249 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"1432_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/nrd3368","volume":"10","author":"R MacArron","year":"2011","unstructured":"MacArron, R. et al. Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov. 10, 188\u2013195 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1432_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrd.2016.213","volume":"16","author":"RA Goodnow","year":"2017","unstructured":"Goodnow, R. A., Dumelin, C. E. & Keefe, A. D. DNA-encoded chemistry: enabling the deeper sampling of chemical space. Nat. Rev. Drug Discov. 16, 131\u2013147 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1432_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-biochem-062917-012550","volume":"8","author":"D Neri","year":"2018","unstructured":"Neri, D. & Lerner, R. A. DNA-encoded chemical libraries: a selection system based on endowing organic compounds with amplifiable information. Annu. Rev. Biochem. 8, 479\u2013502 (2018).","journal-title":"Annu. Rev. Biochem."},{"key":"1432_CR18","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1126\/science.350.6265.1139","volume":"350","author":"T Gura","year":"2015","unstructured":"Gura, T. DNA helps build molecular libraries for drug testing. Science 350, 1139\u20131140 (2015).","journal-title":"Science"},{"key":"1432_CR19","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/nprot.2016.039","volume":"11","author":"W Decurtins","year":"2016","unstructured":"Decurtins, W. et al. Automated screening for small organic ligands using DNA-encoded chemical libraries. Nat. Protoc. 11, 764\u2013780 (2016).","journal-title":"Nat. Protoc."},{"key":"1432_CR20","doi-asserted-by":"publisher","first-page":"17670","DOI":"10.1073\/pnas.0805130105","volume":"105","author":"L Mannocci","year":"2008","unstructured":"Mannocci, L. et al. High-throughput sequencing allows the identification of binding molecules isolated from DNA-encoded chemical libraries. Proc. Natl Acad. Sci. USA 105, 17670\u201317675 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1432_CR21","doi-asserted-by":"publisher","first-page":"9839","DOI":"10.1158\/0008-5472.CAN-08-2341","volume":"68","author":"CP Leamon","year":"2008","unstructured":"Leamon, C. P. et al. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Cancer Res. 68, 9839\u20139844 (2008).","journal-title":"Cancer Res."},{"key":"1432_CR22","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1158\/1078-0432.CCR-17-3457","volume":"24","author":"S Cazzamalli","year":"2018","unstructured":"Cazzamalli, S. et al. Enhanced therapeutic activity of non-internalizing small-molecule\u2013drug conjugates targeting carbonic anhydrase IX in combination with targeted interleukin-2. Clin. Cancer Res. 24, 3656\u20133667 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1432_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1073\/pnas.2101852118","volume":"118","author":"J Millul","year":"2021","unstructured":"Millul, J. et al. An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications. Proc. Natl Acad. Sci. USA 118, 1\u201310 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1432_CR24","doi-asserted-by":"publisher","first-page":"15894","DOI":"10.1021\/acs.jmedchem.3c01355","volume":"66","author":"F Krutzek","year":"2023","unstructured":"Krutzek, F., Donat, C. K., Ullrich, M. & Stadlbauer, S. Design, synthesis, and biological evaluation of small-molecule-based radioligands with improved pharmacokinetic properties for imaging of programmed death ligand 1. J. Med. Chem. 66, 15894\u201315915 (2023).","journal-title":"J. Med. Chem."},{"key":"1432_CR25","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1007\/s00259-022-05821-w","volume":"49","author":"EAM Ruigrok","year":"2022","unstructured":"Ruigrok, E. A. M. et al. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T. Eur. J. Nucl. Med. Mol. Imaging 49, 3627\u20133638 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1432_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canep.2020.101833","volume":"69","author":"NH Thurin","year":"2020","unstructured":"Thurin, N. H. et al. Epidemiology of metastatic castration-resistant prostate cancer: a first estimate of incidence and prevalence using the French nationwide healthcare database. Cancer Epidemiol. 69, 1\u20136 (2020).","journal-title":"Cancer Epidemiol"},{"key":"1432_CR27","unstructured":"Cancer in men: prostate cancer is #1 for 118 countries globally. American Cancer Society https:\/\/www.cancer.org\/research\/acs-research-news\/prostate-cancer-is-number-1-for-118-countries-worldwide.html (2024)."},{"key":"1432_CR28","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.2967\/jnumed.123.266141","volume":"64","author":"S Satapathy","year":"2023","unstructured":"Satapathy, S. et al. [177Lu]Lu-PSMA-617 versus docetaxel in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: final survival analysis of a phase 2 randomized, controlled trial. J. Nucl. Med. 64, 1726\u20131729 (2023).","journal-title":"J. Nucl. Med."},{"key":"1432_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tranon.2022.101445","volume":"21","author":"S Mahajan","year":"2022","unstructured":"Mahajan, S., Grewal, R. K., Friedman, K. P., Sch\u00f6der, H. & Pandit-Taskar, N. Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: current concepts in imaging and management. Transl. Oncol. 21, 1\u20138 (2022).","journal-title":"Transl. Oncol"},{"key":"1432_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","volume":"98\u201399","author":"N Heynickx","year":"2021","unstructured":"Heynickx, N., Herrmann, K., Vermeulen, K., Baatout, S. & Aerts, A. The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: a review of the lessons learnt so far. Nucl. Med. Biol. 98\u201399, 30\u201339 (2021).","journal-title":"Nucl. Med. Biol."},{"key":"1432_CR31","unstructured":"Expression of ACP3 in tumors and healthy organs (IHC). The Human Protein Atlas https:\/\/www.proteinatlas.org\/ENSG00000014257-ACP3 (2024)."},{"key":"1432_CR32","doi-asserted-by":"publisher","first-page":"10438","DOI":"10.3390\/ijms140510438","volume":"14","author":"S Muniyan","year":"2013","unstructured":"Muniyan, S. et al. Human prostatic acid phosphatase: structure, function and regulation. Int. J. Mol. Sci. 14, 10438\u201310464 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"1432_CR33","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1158\/0008-5472.CAN-07-1651","volume":"67","author":"IB Quintero","year":"2007","unstructured":"Quintero, I. B. et al. Prostatic acid phosphatase is not a prostate specific target. Cancer Res. 67, 6549\u20136554 (2007).","journal-title":"Cancer Res."},{"key":"1432_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/pros.2990110107","volume":"11","author":"P Vihko","year":"1987","unstructured":"Vihko, P. et al. Immunoscintigraphic evaluation of lymph node involvement in prostatic carcinoma. Prostate 11, 51\u201357 (1987).","journal-title":"Prostate"},{"key":"1432_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0001-2998(89)80023-6","volume":"XIX","author":"RJ Babaian","year":"1989","unstructured":"Babaian, R. J. & Lamki, L. M. Radioimmunoscintigraphy of prostate cancer. Semin. Nucl. Med. XIX, 309\u2013321 (1989).","journal-title":"Semin. Nucl. Med."},{"key":"1432_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0160890","volume":"11","author":"AB Waight","year":"2016","unstructured":"Waight, A. B. et al. Structural basis of microtubule destabilization by potent auristatin anti-mitotics. PLoS ONE 11, 1\u201314 (2016).","journal-title":"PLoS ONE"},{"key":"1432_CR37","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1021\/acs.bioconjchem.7b00304","volume":"28","author":"A Dal Corso","year":"2017","unstructured":"Dal Corso, A., Cazzamalli, S., G\u00e9bleux, R., Mattarella, M. & Neri, D. Protease-cleavable linkers modulate the anticancer activity of noninternalizing antibody\u2013drug conjugates. Bioconjugate Chem. 28, 1826\u20131833 (2017).","journal-title":"Bioconjugate Chem"},{"key":"1432_CR38","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt832","volume":"21","author":"SO Doronina","year":"2003","unstructured":"Doronina, S. O. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778\u2013784 (2003).","journal-title":"Nat. Biotechnol."},{"key":"1432_CR39","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/s41557-023-01257-3","volume":"15","author":"S Oehler","year":"2023","unstructured":"Oehler, S. et al. A DNA-encoded chemical library based on chiral 4-amino-proline enables stereospecific isozyme-selective protein recognition. Nat. Chem. 15, 1431\u20131443 (2023).","journal-title":"Nat. Chem."},{"key":"1432_CR40","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41557-021-00660-y","volume":"13","author":"N Favalli","year":"2021","unstructured":"Favalli, N. et al. Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications. Nat. Chem. 13, 540\u2013548 (2021).","journal-title":"Nat. Chem."},{"key":"1432_CR41","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/0968-0896(96)00186-1","volume":"4","author":"SA Beers","year":"1996","unstructured":"Beers, S. A. Phosphatase inhibitors-lll. Benzylamino phosphonicacids as potent inhibitors of human prostatic acid phosphatase. Bioorg. Med. Chem. 4, 1693\u20131701 (1996).","journal-title":"Bioorg. Med. Chem."},{"key":"1432_CR42","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1007\/s00259-024-06704-y","volume":"51","author":"G Bao","year":"2024","unstructured":"Bao, G. et al. Targeting CXCR4\/CXCL12 axis via [177Lu]Lu-DOTAGA.(SA.FAPi)2 with CXCR4 antagonist in triple-negative breast cancer. Eur. J. Nucl. Med. Mol. Imaging 51, 2744\u20132757 (2024).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1432_CR43","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1007\/s00259-021-05653-0","volume":"49","author":"P Backhaus","year":"2022","unstructured":"Backhaus, P. et al. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA. Eur. J. Nucl. Med. Mol. Imaging 49, 1822\u20131832 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1432_CR44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd4519","volume":"14","author":"M Srinivasarao","year":"2015","unstructured":"Srinivasarao, M., Galliford, C. V. & Low, P. S. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat. Rev. Drug Discov. 14, 203\u2013219 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1432_CR45","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil, C. et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J. Nucl. Med. 57, 1170\u20131176 (2016).","journal-title":"J. Nucl. Med."},{"key":"1432_CR46","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2165\/00003088-200241100-00005","volume":"41","author":"MS Roberts","year":"2002","unstructured":"Roberts, M. S., Magnusson, B. M., Burczynski, F. J. & Weiss, M. Enterohepatic circulation. Clin. Pharmacokinet. 41, 751\u2013790 (2002).","journal-title":"Clin. Pharmacokinet."},{"key":"1432_CR47","first-page":"942","volume":"40","author":"C Fleck","year":"1990","unstructured":"Fleck, C. & Br\u00e4unlich, H. Factors determining the relationship between renal and hepatic excretion of xenobiotics. Arzneimittelforschung 40, 942\u2013946 (1990).","journal-title":"Arzneimittelforschung"},{"key":"1432_CR48","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.2967\/jnumed.123.265484","volume":"64","author":"J Hemmingsson","year":"2023","unstructured":"Hemmingsson, J. et al. Specific uptake in the bone marrow causes high absorbed red marrow doses during [177Lu]Lu-DOTATATE treatment. J. Nucl. Med. 64, 1456\u20131462 (2023).","journal-title":"J. Nucl. Med."},{"key":"1432_CR49","doi-asserted-by":"publisher","first-page":"5440","DOI":"10.1158\/1078-0432.CCR-22-1788","volume":"28","author":"A Zana","year":"2022","unstructured":"Zana, A. et al. Fibroblast activation protein triggers release of drug payload from non-internalizing small molecule drug conjugates in solid tumors. Clin. Cancer Res. 28, 5440\u20135454 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1432_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nchem.2158","volume":"7","author":"M Wichert","year":"2015","unstructured":"Wichert, M. et al. Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation. Nat. Chem. 7, 241\u2013249 (2015).","journal-title":"Nat. Chem."},{"key":"1432_CR51","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.chempr.2022.10.006","volume":"9","author":"S Puglioli","year":"2023","unstructured":"Puglioli, S. et al. Selective tumor targeting enabled by picomolar fibroblast activation protein inhibitors isolated from a DNA-encoded affinity maturation library. Chem 9, 411\u2013429 (2023).","journal-title":"Chem"},{"key":"1432_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00259-018-4189-7","volume":"46","author":"F Ceci","year":"2019","unstructured":"Ceci, F. et al. 68Ga-PSMA-11 PET\/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur. J. Nucl. Med. Mol. Imaging 46, 31\u201339 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1432_CR53","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet, J. et al. Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J. Nucl. Med. 60, 517\u2013523 (2019).","journal-title":"J. Nucl. Med."},{"key":"1432_CR54","doi-asserted-by":"publisher","first-page":"14","DOI":"10.23736\/S1824-4785.22.03502-6","volume":"67","author":"L Cunha","year":"2023","unstructured":"Cunha, L., Baete, K., Leijen, C. & Jamar, F. Main challenges in radiation protection with emerging radionuclide therapies. Quart. J. Nucl. Med. Mol. Imaging 67, 14\u201328 (2023).","journal-title":"Quart. J. Nucl. Med. Mol. Imaging"},{"key":"1432_CR55","doi-asserted-by":"publisher","unstructured":"Georgiev, T. et al. Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy. figshare https:\/\/doi.org\/10.6084\/m9.figshare.28668596 (2025).","DOI":"10.6084\/m9.figshare.28668596"},{"key":"1432_CR56","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.nucmedbio.2019.04.005","volume":"71","author":"SK Sharma","year":"2019","unstructured":"Sharma, S. K. et al. A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals. Nucl. Med. Biol. 71, 32\u201338 (2019).","journal-title":"Nucl. Med. Biol."},{"key":"1432_CR57","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.2967\/jnumed.122.264036","volume":"63","author":"A Galbiati","year":"2022","unstructured":"Galbiati, A. et al. A dimeric FAP-targeting small-molecule radioconjugate with high and prolonged tumor uptake. J. Nucl. Med. 63, 1852\u20131858 (2022).","journal-title":"J. Nucl. Med."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01432-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01432-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01432-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T23:03:22Z","timestamp":1769036602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01432-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1432"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01432-6","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"8 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.N. is the co-founder, CEO, CSO and president of the Scientific Advisory Board of Philogen. T.G., F.M., I.B., M.M., Y.S.P.K., L.P., E.G., N.F., E.P., S.O. and S.C. are employed by Philochem AG, the research and development unit of the Philogen group. Some of the findings included in this manuscript have been patented. T.G., F.M., S.O., S.C., D.N. and Y.S.P.K. are listed in the patent application PCT\/EP2024\/080350 (filed on 25 October 2024). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}